Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2008-2231
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis ; volume:25 ; number:1 ; day:20 ; month:4 ; year:2017 ; pages:1-8 ; date:12.2017
DARU ; 25, Heft 1 (20.4.2017), 1-8, 12.2017
- Creator
-
Dolatimehr, Fardin
- Contributor
-
Karimi-Sari, Hamidreza
Rezaee-Zavareh, Mohammad Saeid
Alavian, Seyed Moayed
Behnava, Bita
Gholami-Fesharaki, Mohammad
Sharafi, Heidar
SpringerLink (Online service)
- DOI
-
10.1186/s40199-017-0177-x
- URN
-
urn:nbn:de:1111-201705049449
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dolatimehr, Fardin
- Karimi-Sari, Hamidreza
- Rezaee-Zavareh, Mohammad Saeid
- Alavian, Seyed Moayed
- Behnava, Bita
- Gholami-Fesharaki, Mohammad
- Sharafi, Heidar
- SpringerLink (Online service)
Other Objects (12)
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection